Trials / Completed
CompletedNCT05413044
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 140,706 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect real-world data in order to estimate the frequency of overall malignancies, melanoma, basal cell carcinoma, and squamous cell carcinoma in participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) enrolled in the SRQ Register in Sweden.
Conditions
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2025-08-22
- Completion
- 2025-10-31
- First posted
- 2022-06-09
- Last updated
- 2025-12-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05413044. Inclusion in this directory is not an endorsement.